Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.

He H, Yin JY, Xu YJ, Li X, Zhang Y, Liu ZG, Zhou F, Zhai M, Li Y, Li XP, Wang Y, Zhou HH, Liu ZQ.

Clin Ther. 2014 Aug 1;36(8):1242-1252.e2. doi: 10.1016/j.clinthera.2014.06.016. Epub 2014 Jul 8.

PMID:
25012726
2.

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.

Perwitasari DA, Wessels JA, van der Straaten RJ, Baak-Pablo RF, Mustofa M, Hakimi M, Nortier JW, Gelderblom H, Guchelaar HJ.

Jpn J Clin Oncol. 2011 Oct;41(10):1168-76. doi: 10.1093/jjco/hyr117. Epub 2011 Aug 11.

PMID:
21840870
3.

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.

Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H.

Cancer. 2010 Dec 15;116(24):5659-66. doi: 10.1002/cncr.25365.

4.

Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.

He H, Yin J, Li X, Zhang Y, Xu X, Zhai M, Chen J, Qian C, Zhou H, Liu Z.

Eur J Clin Pharmacol. 2015 Mar;71(3):293-302. doi: 10.1007/s00228-014-1795-6. Epub 2015 Jan 9.

PMID:
25567217
5.

Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients.

Kang G, Kim KR, Shim HJ, Hwang JE, Bae WK, Chung IJ, Kim HN, Lee J, Choi K, Shin HY, Kim JK, Jeong SW, Cho SH.

Asia Pac J Clin Oncol. 2017 Feb;13(1):53-60. doi: 10.1111/ajco.12575. Epub 2016 Aug 4.

PMID:
27488933
6.

Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.

Holdsworth MT, Raisch DW, Winter SS, Chavez CM.

Support Care Cancer. 1998 Mar;6(2):132-8.

PMID:
9540172
7.

Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.

Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A.

Clin Pharmacol Ther. 2005 Dec;78(6):619-26.

PMID:
16338277
8.

Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.

Zoto T, Kilickap S, Yasar U, Celik I, Bozkurt A, Babaoglu MO.

Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):354-60. doi: 10.1111/bcpt.12334. Epub 2014 Nov 6.

9.

Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?

Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A.

J Oncol Pharm Pract. 2007 Jun;13(2):69-75.

PMID:
17873106
10.

Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.

Holdsworth MT, Raisch DW, Duncan MH, Chavez CM, Leasure MM.

Ann Pharmacother. 1995 Jan;29(1):16-21.

PMID:
7711340
11.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
12.

The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?

Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, Nikoloff M, Wu L, Andrews D.

Anesthesiology. 2005 Mar;102(3):543-9.

PMID:
15731591
13.

[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].

Kodama F, Mohri H, Motomura S, Fukawa H, Tanabe J, Koharasawa H, Kanamori H, Hashimoto Y, Harano H, Sakai R, Tomita N, Fujimaki K, Takemura S, Hattori M.

Gan To Kagaku Ryoho. 2002 Feb;29(2):273-9. Japanese.

PMID:
11865634
14.
15.

Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting.

Choi EM, Lee MG, Lee SH, Choi KW, Choi SH.

Anaesthesia. 2010 Oct;65(10):996-1000. doi: 10.1111/j.1365-2044.2010.06476.x.

16.
18.

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine.

Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G.

Biomed Res Int. 2015;2015:497597. doi: 10.1155/2015/497597. Epub 2015 Jan 15.

19.

Influence of genetic variations in ABCB1 on the clinical efficacy of ondansetron - A pharmacogenetic analysis of Pakistani population.

Farhat K, Waheed A, Hussain A, Ismail M, Mansoor Q, Pasha AK, Jafery N.

J Pak Med Assoc. 2015 Sep;65(9):963-6.

20.

Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.

Peterson C, Hursti TJ, Börjeson S, Avall-Lundqvist E, Fredrikson M, Fürst CJ, Lomberg H, Steineck G.

Support Care Cancer. 1996 Nov;4(6):440-6.

PMID:
8961475

Supplemental Content

Support Center